Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

被引:23
|
作者
Li, Qing [1 ]
Xiang, Ming [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Dept Pharmacol, Wuhan 430000, Peoples R China
来源
ACTA PHARMACOLOGICA SINICA | 2022年 / 43卷 / 06期
基金
中国国家自然科学基金;
关键词
myeloid-derived suppressor cells; tumor microenvironment; metabolic reprograming; cancer immunotherapy; metabolic intervention; A2A ADENOSINE RECEPTOR; HUMAN BREAST-CANCER; SUPPRESSOR-CELLS; IMMUNE SUPPRESSION; LUNG-CANCER; ACID; EXPRESSION; IMMUNOSUPPRESSION; CHOLESTEROL; RESPONSES;
D O I
10.1038/s41401-021-00776-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A number of emerging studies in field of immune metabolism have indicated that cellular metabolic reprograming serves as a major administrator in maintaining the viability and functions of both tumor cells and immune cells. As one of the most important immunosuppressive cells in tumor stroma, myeloid-derived suppressor cells (MDSCs) dynamically orchestrate their metabolic pathways in response to the complicated tumor microenvironment (TME), a process that consequently limits the therapeutic effectiveness of anti-cancer treatment modalities. In this context, the metabolic vulnerabilities of MDSCs could be exploited as a novel immune metabolic checkpoint upon which to intervene for promoting the efficacy of immunotherapy. Here, we have discussed about recent studies highlighting the important roles of the metabolic reprograming and the core molecular pathways involved in tumor-infiltrating MDSCs. In addition, we have also summarized the state-of-the-art strategies that are currently being employed to target MDSC metabolism and improve the efficacy of antineoplastic immunotherapy.
引用
收藏
页码:1337 / 1348
页数:12
相关论文
共 50 条
  • [11] Targeting the tumor microenvironment to enhance immunotherapy against cancer
    Slaney, Clare Y.
    Oliver, Amanda J.
    Kershaw, Michael H.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [12] The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
    Yang, Muyue
    Li, Jipeng
    Gu, Ping
    Fan, Xianqun
    BIOACTIVE MATERIALS, 2021, 6 (07) : 1973 - 1987
  • [13] Targeting monoclonal antibodies to the tumor microenvironment for cancer immunotherapy
    Hall, Frederick L.
    Chawla, Sant P.
    Chawla, Neal S.
    Gordon, Erlinda M.
    CANCER RESEARCH, 2016, 76
  • [14] Toward integrative cancer immunotherapy: targeting the tumor microenvironment
    Leisha A Emens
    Samuel C Silverstein
    Samir Khleif
    Francesco M Marincola
    Jérôme Galon
    Journal of Translational Medicine, 10
  • [15] Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
    Bader, Jackie E.
    Voss, Kelsey
    Rathmell, Jeffrey C.
    MOLECULAR CELL, 2020, 78 (06) : 1019 - 1033
  • [16] Toward integrative cancer immunotherapy: targeting the tumor microenvironment
    Emens, Leisha A.
    Silverstein, Samuel C.
    Khleif, Samir
    Marincola, Francesco M.
    Galon, Jerome
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [17] Targeting Immunotherapy to the Tumor Microenvironment
    Dougan, Michael
    Dougan, Stephanie K.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2017, 118 (10) : 3049 - 3054
  • [18] Improving cancer immunotherapy by targeting the STATe of MDSCs
    de Haas, Nienke
    de Koning, Coco
    Spilgies, Lisanne
    de Vries, I. Jolanda M.
    Hato, Stanleyson V.
    ONCOIMMUNOLOGY, 2016, 5 (07):
  • [19] A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy
    Sau, Samaresh
    Tatiparti, Katyayani
    Alsaab, Hashem O.
    Kashaw, Sushi K.
    Iyer, Arun K.
    DRUG DISCOVERY TODAY, 2018, 23 (07) : 1344 - 1356
  • [20] Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief
    He, Mengying
    Zhang, Mengyao
    Xu, Tao
    Xue, Shujuan
    Li, Dazhao
    Zhao, Yanan
    Zhi, Feng
    Ding, Dawei
    JOURNAL OF CONTROLLED RELEASE, 2024, 368 : 233 - 250